Drug Profile
Lutetium-177 DOTA EB TATE - Molecular Targeting Technologies
Alternative Names: 177Lu-DOTA-EB-TATE; 177Lu-DOTA-EB-TATE - Molecular Targeting Technologies; EBTATE; Lutetium-177-DOTA-EB-TATELatest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator National Institute of Biomedical Imaging and Bioengineering
- Developer Molecular Targeting Technologies
- Class Antineoplastics; Drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Nasopharyngeal cancer; Neuroendocrine tumours; Thyroid cancer
Most Recent Events
- 27 Feb 2024 Phase-I clinical trials in Nasopharyngeal cancer in Singapore (IV) prior to February 2024 (Molecular Targeting Technologies pipeline, February 2024)
- 27 Feb 2024 Phase-I clinical trials in Thyroid cancer in USA (IV) prior to February 2024 (Molecular Targeting Technologies pipeline, February 2024)
- 29 Sep 2023 Pharmacokinetics, adverse events and efficacy data from a phase I trial in Neuroendocrine tumours released by Molecular Targeting Technologies